CorMedix heads into July with a stubborn short base, a stock down nearly 9% on the week, and an August earnings date that is moving from background noise to front-of-mind.
The short side of the ledger is the defining feature here. Short interest has climbed 3% over the past week to 18.3% of the free float — roughly 14.5 million shares — a level that puts CRMD firmly in the heavily-shorted tier of small-cap pharma. The month-long trend tells a more nuanced story: SI is actually 11% lower than it was thirty days ago, having pulled back from a period when the borrow pool was almost completely exhausted. Availability has recovered meaningfully from near-zero readings in early June, when just 0.4% of the lending pool remained undeployed, to 13.4% today — still tight by any standard, but the loosening represents a genuine shift in the borrow dynamic. Cost to borrow has risen 39% over the week to 1.42%, a modest absolute level but a notable directional tick given how cheap it had been running through mid-June. The options market is telling a different story from the short sellers: the put/call ratio has dropped to 0.49, almost 1.7 standard deviations below its 20-day average of 0.60, suggesting options traders are positioned more bullishly than usual — a contrast worth sitting with.
The Street is constructive but not crowded. All tracked analysts carry buy-equivalent ratings, with a mean price target of $15.20 against a $7.85 close — implying roughly 94% upside on consensus. That gap looks stark, but the analyst as_of dates run to late April, so the targets trail the stock's recent weakness. The bull case centres on DefenCath's commercial trajectory in catheter-related bloodstream infections among hemodialysis patients, with forecasters pointing toward peak sales approaching $190 million in its current indication by 2030. Bears focus on differentiation risk — whether DefenCath's safety profile offers enough daylight from competing prophylaxis options — and execution uncertainty around the Melinta asset acquisition. The ORTEX short score sits at 81.9, ranking in the bottom 2nd percentile of the universe on short positioning metrics, a quantitative flag that reinforces the narrative around elevated short pressure. EPS surprise ranks in the 82nd percentile, a reminder that the company has been beating estimates consistently even as the stock has drifted lower.
Ownership offers one interesting wrinkle. Deep Track Capital, a healthcare-focused fund, holds nearly 8% of shares — the largest disclosed institutional position — and added 1 million shares in the most recent filing period. UBS Asset Management also added substantially, bringing its stake to roughly 2.2% of the company. Those moves, reported through March 31, predate the stock's recent slide, but they indicate that some institutional buyers were active at higher prices. Insider activity, however, has been one-directional: the CEO, CFO, COO, and Chief Legal Officer all sold shares in January, ranging from small routine disposals to the CEO's combined 67,000 shares across three transactions. None of the trades were large in absolute dollar terms, but the cluster of C-suite selling at prices around $6.80–$7.27 — near the current level — is worth noting as context.
The earnings history adds a layer of asymmetry. The most recent event, on June 23, produced a 4.9% one-day decline and a 11% five-day loss. The prior print, in May, went the other way — up 0.7% on the day and 7.5% over five days. With Q2 results due August 7, the short base at 18% of float and availability still in tight territory means the setup for any positive surprise carries potential for a sharp unwind. Comparable-week peers were broadly weaker: AQST fell 17% over the week and OMER dropped 9%, suggesting sector-level pressure rather than CRMD-specific selling.
The August 7 print is now the focal point — specifically whether DefenCath's commercial uptake data closes any of the gap between a $7.85 stock and a Street consensus clustered in the mid-teens.
See the live data behind this article on ORTEX.
Open CRMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
